Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists

• US 9,775,904 B2
• Filed: 04/06/2015
• Issued: 10/03/2017
• Est. Priority Date: 04/07/2014
• Status: Active Grant

• Current Assignee: Sanofi
• Original Assignee: Sanofi
• Inventors: Bossart, Martin, Elvert, Ralf, Evers, Andreas, Haack, Torsten, Stengelin, Siegfried, Wagner, Michael
• Primary Examiner(s): Ha, Julie
• Assistant Examiner(s): Hellman, Kristina M
• Application Number:
  US14/679,743
• Publication Number:
  US 20150315260A1
• Time in Patent Office: 911 Days
• Field of Search: None
• CPC Class Codes: A61K 38/2278 Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07K 14/46 from vertebrates

Abstract

The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Claims

1. A peptidic compound of formula (I):

2. The compound or salt or solvate thereof of claim 1, wherein R¹ is NH₂.

3. The compound or salt or solvate thereof according to claim 1, wherein the peptidic compound has a relative activity of at least 0.09% compared to that of natural glucagon at the glucagon receptor.

4. The compound or salt or solvate thereof according to claim 1, wherein the peptidic compound exhibits a relative activity of at least 0.1% compared to that of a glucagon-like peptide (GLP-1)(7-36)-amide at the GLP-1 receptor.

5. The compound or salt or solvate thereof according to claim 1, wherein

X14 is Lys, wherein the —

NH₂ side chain group is functionalized with a group —

Z—

C(O)R⁵, wherein Z is a group selected from the group consisting of γ

E, γ

E-γ

E, AEEAc-AEEAc-γ

E, and AEEAc-AEEAc-AEEAc, and

R⁵ is a group selected from the group consisting of pentadecanyl, heptadecanyl, and 16-carboxy hexadecanyl.

6. The compound or salt or solvate thereof according to claim 1, wherein X14 is Lys, wherein the —

NH₂ side chain group is functionalized with a group —

Z—

C(O)R⁵, wherein Z is a group selected from the group consisting of γ

E, γ

E-γ

E, AEEAc-AEEAc-γ

E, and AEEAc-AEEAc-AEEAc, and

R⁵ is a group selected from the group consisting of pentadecanyl and heptadecanyl.

7. The compound or salt or solvate thereof according to claim 1, wherein

X14 is Lys, wherein the —

NH₂ side chain group is functionalized by a group selected from the group consisting of (S)-4-Carboxy-4-hexadecanoylamino-butyryl-, (S)-4-Carboxy-4-octadecanoylamino-butyryl-, (S)-4-Carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-, (2-{2-[2-(2-{2-[(4S)-4-Carboxy-4-hexadecanoylamino-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl, and (2-{2-[2-(2-{2-[(4S)-4-Carboxy-4-octadecanoylamino-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl, [2-(2-{2-[2-(2-{2-[2-(2-Octadecanoylamino-ethoxy)-ethoxy]-acetylamino}-ethoxy)-ethoxy]-acetylamino}-ethoxy)-ethoxy]-acetyl-,

X28 is Ala,

X29 is an amino acid residue selected from the group consisting of D-Ala and Gly, and

R¹ is NH₂.

8. The compound or salt or solvate thereof according to claim 1, wherein

X14 is Lys, wherein the —

NH₂ side chain group is functionalized by (S)-4-Carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-,

X28 is Ser,

X29 is an amino acid residue selected from the group consisting of D-Ala and Gly, and

R¹ is NH₂.

9. The compound or salt or solvate thereof according to claim 1, wherein

X14 is Lys, wherein the —

NH₂ side chain group is functionalized by (S)-4-carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-,

X28 is Lys,

X29 is an amino acid residue selected from the group consisting of D-Ala and Gly, and

R¹ is NH₂.

10. The compound or salt or solvate thereof according to claim 1, wherein

X14 is Lys, wherein the —

NH₂ side chain group is functionalized by a group selected from the group consisting of (S)-4-Carboxy-4-hexadecanoylamino-butyryl-, (S)-4-Carboxy-4-octadecanoylamino-butyryl-, and (S)-4-Carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-,

X28 is an amino acid residue selected from the group consisting of Ala, Lys, and Ser,

X29 is D-Ala, and

R¹ is NH₂.

11. The compound or salt or solvate thereof of claim 1, wherein

X14 is Lys, wherein the —

NH₂ side chain group is functionalized by a group selected from the group consisting of (S)-4-Carboxy-4-hexadecanoylamino-butyryl-, (S)-4-Carboxy-4-octadecanoylamino-butyryl-, (S)-4-Carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-, (2-{2-[2-(2-{2-[(4S)-4-Carboxy-4-hexadecanoylamino-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl, and (2-{2-[2-(2-{2-[(4S)-4-Carboxy-4-octadecanoylamino-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl, [2-(2-{2-[2-(2-{2-[2-(2-Octadecanoylamino-ethoxy)-ethoxy]-acetylamino}-ethoxy)-ethoxy]-acetylamino}-ethoxy)-ethoxy]-acetyl-,

X28 is an amino acid residue selected from the group consisting of Ala, Lys, and Ser,

X29 is Gly, and

R¹ is NH₂.

12. The compound or salt or solvate thereof of claim 1, wherein

X14 is Lys, wherein the —

NH₂ side chain group is functionalized by (S)-4-Carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-,

X28 is Ala,

X29 is an amino acid residue selected from the group consisting of Gly and D-Ala, and

R¹ is NH₂.

13. The compound or salt or solvate thereof of claim 1, selected from the compounds of SEQ ID NOs:

6-19, or a salt or solvate thereof.

14. The compound or salt or solvate thereof of claim 13, selected from the compounds of SEQ ID NOs:

6-18, or a salt or solvate thereof.

15. The compound, salt or solvate according to claim 1, wherein the compound is the amino acid sequence of SEQ ID NO:

7.

16. The compound, salt or solvate according to claim 1, wherein the compound is the amino acid sequence of SEQ ID NO:

8.

17. A solvate of a compound of claim 1.

18. A hydrate of a compound of claim 1.

19. A pharmaceutical composition comprising one or more compounds of claim 1, or a salt or solvate thereof as an active ingredient and at least one pharmaceutically acceptable carrier.

20. The pharmaceutical composition according to claim 19, further comprising at least one additional therapeutically active agent, wherein the additional therapeutically active agent is selected from the group consisting of:

insulin and insulin derivatives selected from the group consisting of insulin glargine, insulin glusiline, insulin detemir, insulin lispro, insulin degludec, insulin aspart, basal insulin and analogues thereof, pegylated insulin, recombinant human insulin, polysialated insulins, long-acting insulin, NN1045, insulin in combination with pramlintide, PE0139, fast-acting and short-acting insulins, insulin hydrogel, oral insulin, inhalable insulin, transdermal insulin and sublingual insulin, and insulin derivatives which are bonded to albumin or another protein by a bifunctional linker;

GLP-1;

GLP-1 analogues;

GLP-1 receptor agonists selected from the group consisting of lixisenatide, exenatide, ITCA 650, AC-2993, liraglutide, semaglutide, taspoglutide, albiglutide, dulaglutide, rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide, HM-11260C, CM-3, ORMD-0901, NN-9924, NN-9926, NN-9927, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, xtenylated exenatide, xtenylated glucagon, and polymer bound derivatives thereof;

dual GLP-1/GIP receptor agonists;

dual GLP-1/glucagon receptor agonists;

protein YY_3-36 (PYY3-36);

pancreatic polypeptide;

glucagon receptor agonists;

GIP receptor agonists or antagonists;

ghrelin antagonists or inverse agonists;

xenin;

dipeptidyl peptidase IV (DPP-IV) inhibitors;

sodium glucose cotransporter 2 (SGLT2) inhibitors;

dual SGLT2/SGLT1 inhibitors;

biguanides;

thiazolidinediones;

dual peroxisome proliferator-activated receptor (PPAR) agonists;

sulfonylureas;

meglitinides;

alpha-glucosidase inhibitors;

amylin and pramlintide;

G protein-coupled receptor 119 (GPR119) agonists;

GPR40 agonists;

GPR120 agonists;

GPR142 agonists;

systemic or low-absorbable transmembrane G protein-coupled receptor 5 (TGR5) agonists;

bromocriptine mesylate;

inhibitors of 11-beta-hydroxysteroid dehydrogenase (HSD);

activators of glucokinase;

inhibitors of diacylglycerol acyltransferase (DGAT);

inhibitors of protein tyrosinephosphatase 1;

inhibitors of glucose-6-phosphatase;

inhibitors of fructose-1,6-bisphosphatase;

inhibitors of glycogen phosphorylase;

inhibitors of phosphoenol pyruvate carboxykinase;

inhibitors of glycogen synthase kinase;

inhibitors of pyruvate dehydrogenase kinase;

alpha2-antagonists;

C—

C motif receptor (CCR-2) antagonists;

modulators of glucose transporter-4;

somatostatin receptor 3 agonists;

3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA)-reductase inhibitors;

fibrates;

nicotinic acid and derivatives thereof;

nicotinic acid receptor 1 agonists;

PPAR-alpha, gamma, or alpha/gamma agonists or modulators;

PPAR-delta agonists;

acyl-CoA cholesterol acyltransferase (ACAT) inhibitors;

cholesterol absorption inhibitors;

bile acid-binding substances;

ileal bile acid transporter (IBAT) inhibitors;

microsomal triglyceride transfer protein (MTP) inhibitors;

modulators of proprotein convertase subtilisin/kinexin type 9 (PCSK9);

low-density lipoprotein (LDL) receptor up-regulators by liver selective thyroid hormone receptor 13 agonists;

high-density lipoprotein (HDL)-raising compounds;

lipid metabolism modulators;

phospholipase A2 (PLA2) inhibitors;

apolipoprotein A1 (ApoA-1) enhancers;

thyroid hormone receptor agonists;

cholesterol synthesis inhibitors;

omega-3 fatty acids and derivatives thereof;

substances for the treatment of obesity selected from the group consisting of sibutramine, tesofensine, tetrahydrolipstatin, cannabinoid-1 (CB-1) receptor antagonists, melanin-concentrating hormone-1 (MCH-1) antagonists, melanocortin 4 (MC4) receptor agonists and partial agonists, neuropeptide Y5 (NPY5) or NPY2 antagonists, NPY4 agonists, beta-3-agonists, leptin or leptin mimetics, agonists of the 5-hydroxy tryptophan 2c (5HT2c) receptor, combinations of bupropione/naltrexone, combinations of bupropione/zonisamide, combinations of bupropione/phentermine, combinations of pramlintide/metreleptin, and combinations of phentermine/topiramate; and

lipase inhibitors;

angiogenesis inhibitors;

H3 antagonists;

Agouti-related protein (AgRP) inhibitors;

triple monoamine uptake inhibitors;

methionine aminopeptidase type 2 (MetAP2) inhibitors;

nasal formulation of the calcium channel blocker diltiazem;

antisense molecules against production of fibroblast growth factor receptor 4;

prohibitin targeting peptide-1; and

drugs for influencing high blood pressure, chronic heart failure, or atherosclerosis selected from the group consisting of angiotensin II receptor antagonists, angiotensin-converting-enzyme (ACE) inhibitors, endothelin-converting-enzyme (ECE) inhibitors, diuretics, beta-blockers, calcium antagonists, centrally acting hypertensives, antagonists of the alpha-2-adrenergic receptor, inhibitors of neutral endopeptidase, and thrombocyte aggregation inhibitors.

21. A pharmaceutical composition comprising one or more compounds of claim 1, or a physiologically acceptable salt or hydrate thereof as an active ingredient and at least one pharmaceutically acceptable carrier.

22. A method for the treatment of hyperglycemia, type 1 diabetes, type 2 diabetes, or obesity, which comprises administering to a patient in need of such treatment an effective amount of one or more compounds, salts or solvates of claim 1.

23. The method of claim 22, for the treatment or prevention of hyperglycemia, or type 2 diabetes.

24. A method for the simultaneous treatment of diabetes and obesity which comprises administering to a patient in need of such treatment an effective amount of one or more compounds, salts or solvates of claim 1.

25. A method for the treatment hyperglycemia, type 1 diabetes, type 2 diabetes, or obesity, which comprises administering to a patient in need of such treatment an effective amount of a pharmaceutical composition of claim 19.

26. The method of claim 25 for the treatment of hyperglycemia or type 2 diabetes.

27. A method for the simultaneous treatment of diabetes and obesity which comprises administering to a patient in need of such treatment an effective amount of a pharmaceutical composition of claim 19.